The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), characterized in that a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders.本發明係關於含5-氯-N-({(5S)-2-側氧-3-[4-(3-側氧-4-嗎啉基)苯基]-1,3-唑啶-5-基}-甲基)-2-噻吩甲醯胺(利伐沙班(rivaroxaban)，活性化合物(I))之固態口服給藥的醫藥投遞型式，其特徵在於該活性化合物(I)之部分數量係快速釋放且部分數量係以控制之方式(緩和，減緩，延遲)釋放，及關於其等之製備方法，其等作為醫藥品之用途及其等用於預防、二次預防或治療疾病之用途。
